People: BioCryst Pharmaceuticals Inc (BCRX.O)

Summary

Name	Age	Since	Current Position
George Abercrombie		2013	Non-Executive Chairman of the Board
Jon Stonehouse	51	2007	President, Chief Executive Officer, Director
Thomas Staab	44	2013	Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
William Sheridan	57	2008	Senior Vice President, Chief Medical Officer
Yarlagadda Babu	59	2008	Vice President - Drug Discovery
Stanley Erck	64	2008	Independent Director
Nancy Hutson	62	2012	Independent Director
Peder Jensen	57	2011	Independent Director
Kenneth Lee	64	2011	Independent Director
Charles Sanders	80	2009	Independent Director
Rob Bennett			Executive Director - Investor Relations & Communications

» Insider Trading

Biographies

Name	Description
George Abercrombie	Mr. George B. Abercrombie has been Non-Executive Chairman of the Board of BioCryst Pharmaceuticals, Inc., effective May 2013. Mr. Abercrombie has 30 years of experience as a business leader in the pharmaceutical industry. He most recently served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie serves as a member of the Board of Directors of Tranzyme Pharma and as Chairman of the Board of Brickell Biotech and formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc. and Ziopharm Oncology, Inc. Additionally, he is a member of the Board of Directors of Project HOPE and a Senior Scholar at Duke University’s Fuqua School of Business. He served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Public Health.
Jon Stonehouse	Mr. Jon P. Stonehouse is President, Chief Executive Officer, Director of Biocryst Pharmaceuticals Inc. He joined BioCryst in January 2007 as Chief Executive Officer and Director. He was named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and acquisitions, global licensing and business development, corporate strategy and alliance management. In March of 2002, Mr. Stonehouse was appointed Vice President of Global Licensing and Business Development and Integration, where he was responsible for the worldwide licensing and business development activities for the Ethical Pharmaceutical Division of Merck KGaA. Mr. Stonehouse joined EMD Pharmaceuticals, Inc. (the US Ethical Pharma division for Merck KGaA) in December 1999 as Vice President, Licensing and Business Development — Strategy & Integration and IT. Prior to joining Merck KGaA, he held a roles at Astra Merck/AstraZeneca including: Customer Unit Director, Director, Marketing & Sales—IT, National Sales Manager, National Sales Director — Managed Healthcare, and Product Director—Omeprazole (the world’s most widely prescribed prescription drug at that time). Mr. Stonehouse started his career in the pharmaceutical industry as a Sales Representative, National Sales Trainer and District Sales Manager for Merck & Co., Inc. In November 2008, Mr. Stonehouse joined the Advisory Board of Precision Biosciences, Inc., a private biotechnology company. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota.
Thomas Staab	Mr. Thomas R. Staab has been appointed as Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer of BioCryst Pharmaceuticals, Inc., effective January 26, 2013. Prior to that he has served as Chief Financial Officer, Senior Vice President, Treasurer of the Company. Mr. Staab served as Executive Vice President, Chief Financial Officer and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held senior financial positions of acting Chief Financial Officer and Treasurer at Triangle Pharmaceuticals, Inc. through its $465 million acquisition by Gilead Sciences, Inc. in 2003. Before joining Triangle, Mr. Staab spent eight years working for PriceWaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Mr. Staab serves on the Executive Committee of the Board of Directors of the North Carolina Biosciences Organization and is a member of its Audit Committee. He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.
William Sheridan	Dr. William P. Sheridan is Senior Vice President, Chief Medical Officer of Biocryst Pharmaceuticals Inc. Dr. Sheridan spent 15 years in drug development at Amgen Pharmaceuticals, Inc. before joining the Company, most recently as Vice President of North American Medical Affairs from March 2007 to November 2007. Dr. Sheridan organized and led Amgen’s U.S. Medical Affairs function, making contributions to the launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®. In addition to his position at Amgen, Dr. Sheridan held titles at the Vice President level in International Medical Affairs, from March 2005 to February 2007; Global Health Economics, from January 2004 to January 2005; and Outcomes Research, U.S. Medical Affairs and Product Development from January 2002 to December 2003. Prior to joining Amgen, Dr. Sheridan practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria.
Yarlagadda Babu	Dr. Yarlagadda S. Babu is Vice President - Drug Discovery of Biocryst Pharmaceuticals Inc. He joined BioCryst in 1988 and was BioCryst’s first full-time employee. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham.
Stanley Erck	Mr. Stanley C. Erck is an Independent Director of Biocryst Pharmaceuticals Inc., since December 2008. Mr. Erck has served as President, CEO and Director of Novavax, Inc., a publicly traded biopharmaceutical company since 2011, having previously served as Executive Chairman from 2010 to 2011, and he has served as a director of Novavax since 2009. From 2000 through 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a biopharmaceutical company, the company through an initial public offering and a merger with Intercell AG, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, Inc., a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics Inc. (now Genzyme Corp.), and in management positions within Baxter International Inc. In addition to Novavax, Mr. Erck sits on the board of directors of MaxCyte, Inc. and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
Nancy Hutson	Dr. Nancy J. Hutson is an Independent Director of BioCryst Pharmaceuticals, Inc., since January 20, 2012. Dr. Hutson brings 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer, Inc. in 2006 after spending 25 years in several research and leadership positions, most recently serving as Senior Vice President of Global Research & Development (R&D) as well as Director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories. Dr. Hutson received a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. in physiology from Vanderbilt University. Dr. Hutson serves on the Board of Directors for Cubist Pharmaceuticals, Inc. and Endo Pharmaceuticals Holdings, Inc. She also previously served on the Board of Directors of Inspire Pharmaceuticals, Inc. In addition, she is an active member on the Board of Directors for Planned Parenthood of Connecticut. Dr. Hutson is in several professional societies, including but not limited to, the American Association for the Advancement of Science and the American Physiological Society.
Peder Jensen	Dr. Peder K. Jensen is an Independent Director of BioCryst Pharmaceuticals, Inc., since May 3, 2011. Dr. Jensen has 24 years of global drug development experience in both pharmaceutical and biotechnology companies and has been responsible for 40 new drug approvals in the U.S., Europe and Japan during his career. He served as Corporate Senior Vice President and General Manager, Research & Development (R&D) for Japan and Asia/Pacific at Schering-Plough Corporation, a pharmaceutical company, from 2006 to 2010, and earlier he held a number of global senior R&D positions at Schering-Plough, including Executive Vice President of Clinical Research and Chief Medical Officer. Dr. Jensen previously held senior R&D positions at Chiron and Ciba-Geigy, and a number of academic posts. Dr. Jensen received his M.D. from the University of Copenhagen, where he completed his post graduate medical training in neurology and internal medicine. Dr. Jensen is a member of the Boards of Directors of Acorda Therapeutics, Inc. and Five Prime Therapeutics, Inc. Additionally, Dr. Jensen served as a member of the Compensation Committee at Acorda Therapeutics, Inc. Dr. Jensen’s experience in the pharmaceutical and biotechnology industries in a wide range of therapeutic areas, together with his medical training, provide a valued background for service on the Board.
Kenneth Lee	Mr. Kenneth B. Lee is an Independent Director of Biocryst Pharmaceuticals Inc. Mr. Lee has 35 years of experience counseling management teams, boards of directors and investors of technology-based companies worldwide. He is a General Partner with Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was Managing Director of the firm’s health sciences corporate finance group. Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is an active member on the board of directors of biotech companies Maxygen and Pozen, Inc., as well as the North Carolina Biosciences Organization (NCBIO). Previously, Mr. Lee served on the boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, OSI Pharmaceuticals and A.M. Pappas & Associates. He has served in leadership capacities on these boards, including Chairman of the Board, Independent Lead Director and Chairman of Audit Committees.
Charles Sanders	Dr. Charles A. Sanders is an Independent Director of Biocryst Pharmaceuticals Inc. Dr. Sanders is retired from Glaxo, Inc. (now GlaxoSmithKline), a pharmaceutical company, where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. Before joining Glaxo, Dr. Sanders spent eight years with Squibb Corp., where he held a number of posts, including the positions of Vice Chairman, Chief Executive Officer of the Science and Technology Group and Chairman of the Science and Technology Committee of the board of directors. Previously, Dr. Sanders was General Director of Massachusetts General Hospital, Professor of Medicine at Harvard Medical School, Chairman of The Commonwealth Fund and Chairman of the New York Academy of Sciences. He is a graduate of Southwestern Medical College of the University of Texas. Dr. Sanders is a member of the Institute of Medicine of the National Academy of Sciences. He is Chairman Emeritus of Project HOPE and Chairman of the Foundation for the National Institutes of Health, and past Chairman of the UNC Health Care System. Dr. Sanders serves as Chairman and a member of the compensation and governance committees of Biodel, Inc. and has previously served as a director of Icagen, Inc. and Cephalon, Inc. In addition, he serves on the board of directors of the Center for Strategic and International Studies and the GlaxoSmithKline Foundation.
Rob Bennett

Basic Compensation

Name	Fiscal Year Total
George Abercrombie	--
Jon Stonehouse	1,274,880
Thomas Staab	842,202
William Sheridan	722,447
Yarlagadda Babu	621,580
Stanley Erck	--
Nancy Hutson	--
Peder Jensen	--
Kenneth Lee	--
Charles Sanders	--
Rob Bennett	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
George Abercrombie	0	0
Jon Stonehouse	0	0
Thomas Staab	0	0
William Sheridan	22,759	132,284
Yarlagadda Babu	0	0
Stanley Erck	0	0
Nancy Hutson	0	0
Peder Jensen	0	0
Kenneth Lee	0	0
Charles Sanders	0	0
Rob Bennett	0	0

Insider Trading

Name	Shares Traded	Price
ABERCROMBIE GEORGE B	3,000	$1.23
SHERIDAN WILLIAM P	1,789	$1.19
BABU YARLAGADDA S	1,903	$1.19
STONEHOUSE JON P	5,967	$1.19
STAAB THOMAS R II	542	$1.19
STAAB THOMAS R II	2,745	$1.38
STONEHOUSE JON P	3,000	$1.38
SHERIDAN WILLIAM P	3,000	$1.38
BABU YARLAGADDA S	8,500	$0.00
STAAB THOMAS R II	8,500	$0.00
STONEHOUSE JON P	31,300	$0.00
STAAB THOMAS R II	8,500	$0.00
SHERIDAN WILLIAM P	8,500	$0.00
BABU YARLAGADDA S	8,500	$0.00
STONEHOUSE JON P	31,300	$0.00
SHERIDAN WILLIAM P	8,500	$0.00
JENSEN PEDER K	20,000	$1.51
STAAB THOMAS R II	8,113	$3.97
JENSEN PEDER K	20,000	$3.18
STONEHOUSE JON P	13,612	$5.23
LOWREY ROBERT S	2,686	$5.23
BABU YARLAGADDA S	21,038	$0.00
MCCULLOUGH DAVID	15,505	$0.00
STONEHOUSE JON P	41,947	$0.00
STAAB THOMAS R II	11,989	$0.00

» Full list on Insider Trading

People: BioCryst Pharmaceuticals Inc (BCRX.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: